Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers.
about
Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosisIncidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in ChinaCytochrome P450 2E1 gene polymorphisms/haplotypes and anti-tuberculosis drug-induced hepatitis in a Chinese cohortAnti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control studyThe incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1Evaluation of anti-tuberculosis induced adverse reactions in hospitalized patients.Tuberculosis, lung infections, interstitial lung disease, and socioeconomic issues in AJRCCM 2001.Serum protein gamma-glutamyl hydrolase, Ig gamma-3 chain C region, and haptoglobin are associated with the syndromes of pulmonary tuberculosis in traditional Chinese medicine.Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: a retrospective analysis.Microarray expression profile analysis of mRNAs and long non-coding RNAs in pulmonary tuberculosis with different traditional Chinese medicine syndromesCYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study.Lack of association between genetic polymorphisms of CYP3A4, CYP2C9 and CYP2C19 and antituberculosis drug-induced liver injury in a community-based Chinese population.Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?Use of isoniazid for latent tuberculosis infection in a public health clinic.Adverse reactions of anti-tuberculosis drugs in hospitalized patients: incidence, severity and risk factors.
P2860
Q28207601-98EDC5D7-50A8-4C15-9234-A08EC2422514Q28478918-AF74E6A9-1560-4D74-9C52-EB9876045C3AQ28486869-C6B6DE21-EDB2-4106-AB4C-3AF8791A43E3Q28488142-5445799D-0E10-4A6E-ABC7-D2CDD36F1745Q28539060-9A837FF9-CCB1-4DE6-A7AC-DCAB2B3BC1D2Q34145133-32B4331D-10BD-4391-885F-3972E5EDB16FQ34550149-A5BE1FFF-7875-4D1F-9533-405435DDEED3Q35704400-031761BD-3BD6-457A-9BEF-576E80B607A5Q36190248-F120CAC6-2A8E-4535-B7A1-CD5F34A830EAQ36195458-87EAB492-E0C8-4183-B405-047C6450E99FQ43754598-C209C70D-18ED-4A20-82D2-79B269BF8A78Q43885443-D0292F0B-B60E-436F-BBAC-466CEE1D256DQ44225838-50C54040-8A5B-463F-81C6-EC4854B79F07Q44353708-ABD4B602-3A26-4482-93E5-E53D8BA5AECFQ44440459-69471BB5-8055-4D31-A529-5D8DCD6EB415Q51738967-8EAE6161-9966-460F-96BB-C1CCA4049D89
P2860
Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Hepatotoxicity from rifampin p ...... d messages for care providers.
@en
Hepatotoxicity from rifampin p ...... d messages for care providers.
@nl
type
label
Hepatotoxicity from rifampin p ...... d messages for care providers.
@en
Hepatotoxicity from rifampin p ...... d messages for care providers.
@nl
prefLabel
Hepatotoxicity from rifampin p ...... d messages for care providers.
@en
Hepatotoxicity from rifampin p ...... d messages for care providers.
@nl
P2860
P1476
Hepatotoxicity from rifampin p ...... d messages for care providers.
@en
P2093
P2860
P304
P356
10.1164/AJRCCM.164.7.2109052
P407
P577
2001-10-01T00:00:00Z